Sökning: id:"swepub:oai:DiVA.org:uu-348247" >
Safety and Side Eff...
Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
-
- Baygan, Arjang (författare)
- Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
- Aronsson-Kurttila, Wictor (författare)
- Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
- Moretti, Gianluca (författare)
- Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
visa fler...
-
- Tibert, Babylonia (författare)
- Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
- Dahllöf, Göran (författare)
- Karolinska Institutet,Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden
-
- Klingspor, Lena (författare)
- Karolinska Institutet,Uppsala universitet,Klinisk mikrobiologi,Department of Microbiology, Uppsala University Hospital, Uppsala, Sweden
-
- Gustafsson, Britt, 1953- (författare)
- Karolinska Institutet,Uppsala universitet,Barnneurologi/Barnonkologi
-
- Khoein, Bita (författare)
- Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
- Moll, Guido (författare)
- Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
- Hausmann, Charlotta (författare)
- Center for Allogeneic Stem Cell Transplantation, Department of Pathology/Oncology, Karolinska University Hospital, Stockholm, Sweden
-
- Svahn, Britt-Marie (författare)
- Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
- Westgren, Magnus (författare)
- Karolinska Institutet,Department of Obstetrics and Gynecology, Karolinska University Hospital, Stockholm, Sweden
-
- Remberger, Mats (författare)
- Center for Allogeneic Stem Cell Transplantation, Department of Pathology/Oncology, Karolinska University Hospital, Stockholm, Sweden
-
- Sadeghi, Behnam (författare)
- Karolinska Institutet,Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
- Ringden, Olle (författare)
- Karolinska Institutet,Translational Cell Therapy Research Group (TCR), Division of Therapeutic Immunology, Department of LabMed, Karolinska Institutet, Stockholm, Sweden
-
visa färre...
-
(creator_code:org_t)
- 2017-07-11
- 2017
- Engelska.
-
Ingår i: Frontiers in Immunology. - : Frontiers Media SA. - 1664-3224. ; 8
- Relaterad länk:
-
https://doi.org/10.3...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.frontier...
-
https://urn.kb.se/re...
-
https://doi.org/10.3...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Mesenchymal stromal cells (MSCs) are increasingly used in regenerate medicine. Placenta-derived decidual stromal cells (DSCs) are a novel therapy for acute graft-versus-host-disease (GVHD) and hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT). DSCs are more immunosuppressive than MSCs. We assessed adverse events and safety using DSCs among 44 treated patients and 40 controls. The median dose of infused cells was 1.5 (range 0.9–2.9) × 106 DSCs/kg. The patients were given 2 (1–5) doses, with a total of 82 infusions. Monitoring ended 3 months after the last DSC infusion. Three patients had transient reactions during DSC infusion. Laboratory values, hemorrhages, and transfusions were similar in the two groups. The frequency of leukemic relapse (2/2, DSC/controls) and invasive fungal infections (6/6) were the same in the two groups. Causes of death were those seen in HSCT patients: infections (5/3), respiratory failure (1/1), circulatory failure (3/1), thromboembolism (1/0), multiorgan failure (0/1), and GVHD and others (2/7). One-year survival for the DSC patients with GVHD was 67%, which was significantly better than achieved previously at our center. One-year survival was 90% in the DSC-treated HC group. DSC infusions appear safe. Randomized studies are required to prove efficacy.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Immunologi inom det medicinska området (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Immunology in the medical area (hsv//eng)
Nyckelord
- decidual stromal cells
- graft-versus-host disease
- hematopoietic stem cell transplantation
- hemorrhagic cystitis
- mesenchymal stromal cells
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Baygan, Arjang
-
Aronsson-Kurttil ...
-
Moretti, Gianluc ...
-
Tibert, Babyloni ...
-
Dahllöf, Göran
-
Klingspor, Lena
-
visa fler...
-
Gustafsson, Brit ...
-
Khoein, Bita
-
Moll, Guido
-
Hausmann, Charlo ...
-
Svahn, Britt-Mar ...
-
Westgren, Magnus
-
Remberger, Mats
-
Sadeghi, Behnam
-
Ringden, Olle
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Immunologi inom ...
- Artiklar i publikationen
-
Frontiers in Imm ...
- Av lärosätet
-
Uppsala universitet
-
Karolinska Institutet